SpyGlass Pharma Inc Dossier - Source-backed chat

SpyGlass Pharma Inc

SGPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $26.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $886.4M

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

SpyGlass Pharma Inc (Nasdaq: SGP) is a highly innovative, late-stage clinical biopharmaceutical company disrupting the multi-billion dollar glaucoma market. By integrating its proprietary, non-bioerodible drug-eluting pads with a standard monofocal intraocular lens (BIM-IOL System), SpyGlass addresses the critical issue of patient non-compliance (which affects over 75% of glaucoma patients on daily eye drops). The company's technology is highly de-risked because it utilizes bimatoprost, a well-established and FDA-approved active pharmaceutical ingredient, allowing for a streamlined 505(b)(2) regulatory pathway. Backed by a robust cash position of $251 million as of Q1 2026 following its successful February 2026 IPO, SpyGlass has a clear runway through 2028 to complete its parallel Phase 3 trials (SGP-005 and SGP-006) and advance its pipeline, including the standalone Bimatoprost Drug Ring System (BIM-DRS).

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$37.00

Mean target$45.00

High · most bullish analyst$62.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$37.0015%

Phase 3 clinical trial enrollment is delayed beyond 2027, extending the cash burn and requiring dilutive capital raises before FDA approval. The trials show unexpected safety concerns (e.g., localized inflammatory responses or device displacement) or fail to demonstrate non-inferiority to twice-daily timolol. Post-approval adoption is slow due to reimbursement hurdles or surgeon reluctance to shift from traditional therapies, depressing the stock toward the low analyst target of $37.

Base CaseCentral scenario

$45.0050%

Matches the consensus mean

Phase 3 trials complete enrollment in 2027 and meet their co-primary endpoints of non-inferiority in IOP reduction and visual acuity in 2028. The company submits its 505(b)(2) NDA on schedule. Commercial launch begins in late 2028 or early 2029, with steady adoption among cataract surgeons. The cash runway of $251 million successfully funds operations through the clinical readout and NDA submission. The stock trades in line with the consensus analyst price target of $45.

Bull CaseUpside scenario

$62.0035%

The parallel Phase 3 trials (SGP-005 and SGP-006) demonstrate clear non-inferiority to timolol eye drops with an exceptional safety profile, leading to rapid FDA approval in 2028. Cataract surgeons widely adopt the BIM-IOL System because it requires no new surgical techniques and is supported by favorable Category III CPT codes. The standalone BIM-DRS successfully enters clinical trials, expanding the addressable market to pseudophakic glaucoma patients who do not require cataract surgery. Strong commercial execution leads to rapid market penetration, driving the stock toward the high analyst target of $62.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

De-risked clinical profile utilizing bimatoprost, a well-established and highly effective FDA-approved glaucoma medication.
Addresses a massive unmet need in patient non-compliance, with Phase 1/2 data showing 98% of patients remained completely off topical eye drops at 12 months.
Seamless surgical integration that fits into standard cataract procedures without requiring new surgical skills or specialized equipment.
Strong balance sheet with $251 million in cash as of March 31, 2026, providing a runway through 2028 to complete Phase 3 trials.
Favorable regulatory pathway under the FDA's 505(b)(2) process, shortening the timeline to potential commercialization.

Key Investment Risks

Clinical development risk inherent to late-stage Phase 3 trials (SGP-005 and SGP-006), with no guarantee of positive or consistent results.
Pre-revenue, clinical-stage risk with ongoing high cash burn and net losses (-$39.9M net income on a TTM basis).
Commercial adoption risk, as success depends on convincing cataract surgeons to transition to a drug-eluting IOL model and securing favorable reimbursement.
Pipeline concentration, with the company's valuation heavily tied to the success of the bimatoprost-based platform.

Thesis Invalidation Triggers

Failure of either SGP-005 or SGP-006 Phase 3 trials to meet the co-primary endpoint of non-inferiority in IOP reduction compared to timolol.
Occurrence of serious, product-related adverse events during the Phase 3 trials or long-term follow-ups.
Significant delays in Phase 3 enrollment extending completion past 2027, which would severely deplete the cash runway.
Rejection or major delays of the 505(b)(2) NDA submission by the FDA.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.